Rockwell Medical (NASDAQ:RMTI – Get Free Report) and MacroGenics (NASDAQ:MGNX – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Risk & Volatility
Rockwell Medical has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Comparatively, MacroGenics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
Profitability
This table compares Rockwell Medical and MacroGenics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rockwell Medical | -7.98% | -15.41% | -9.62% |
| MacroGenics | -44.79% | -147.80% | -28.40% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rockwell Medical | 1 | 0 | 1 | 0 | 2.00 |
| MacroGenics | 1 | 3 | 3 | 0 | 2.29 |
Rockwell Medical currently has a consensus price target of $2.00, suggesting a potential upside of 220.10%. MacroGenics has a consensus price target of $5.50, suggesting a potential upside of 38.89%. Given Rockwell Medical’s higher probable upside, equities analysts plainly believe Rockwell Medical is more favorable than MacroGenics.
Valuation & Earnings
This table compares Rockwell Medical and MacroGenics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rockwell Medical | $69.26 million | 0.36 | -$5.31 million | ($0.15) | -4.17 |
| MacroGenics | $149.50 million | 1.68 | -$74.62 million | ($1.10) | -3.60 |
Rockwell Medical has higher earnings, but lower revenue than MacroGenics. Rockwell Medical is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 4.6% of Rockwell Medical shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
About Rockwell Medical
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
About MacroGenics
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.
